Your browser does not support iframes.
Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Grifols Sa Barcelona Sponsored ADR
(OP:
GIKLY
)
18.60
USD
UNCHANGED
Last Price
/ Updated:
8:10 PM EDT, Jun 7, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
18.60
Today's Range
18.60 - 18.60
52wk Range
13.46 - 19.81
Shares Outstanding
1,111,914,712
Dividend Yield
N/A
Top News
More News
Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
May 22, 2013
Study results presented at annual meeting of American Thoracic Society (ATS)
Read More
from
PR Newswire
Annual Report for 2012 on Form 20-F filed with the SEC on April 5, 2013
April 05, 2013
from
PR Newswire
More News
Read More
Cadence Pharmaceuticals Announces Strategic Plan to Secure Long-Term Manufacture and Supply of OFIRMEV® (acetaminophen) Injection
March 06, 2013
from
PR Newswire
PROLASTIN® celebrates 25 years as leading augmentation therapy for treatment of alpha(1)-antitrypsin deficiency
February 05, 2013
from
PR Newswire
Grifols Announces First Patient Enrolled and Dosed in Phase II Trial of Alpha-1 HC Aerosol to Treat Cystic Fibrosis
October 08, 2012
from
PR Newswire
Grifols announces robust inventory of HyperRAB® S/D rabies immune globulin for treatment of rabies exposure
September 28, 2012
from
PR Newswire
Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting
September 04, 2012
from
PR Newswire
Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
July 17, 2012
from
PR Newswire
Grifols Publishes Positive Phase I Safety Results for Plasmin, a Novel, Direct-Acting Thrombolytic, in the Journal of Thrombosis and Haemostasis
June 11, 2012
from
PR Newswire
Grifols Annual Report on Form 20-F for 2011 Filed with SEC on March 29, 2012
March 30, 2012
from
PR Newswire
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.